Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 2 |
2024 | 3 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
m6A-dependent upregulation of DDX21 by super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia.
Clin Transl Med. 2024 Apr;14(4):e1628. doi: 10.1002/ctm2.1628.
Clin Transl Med. 2024.
PMID: 38572589
Free PMC article.
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
Zhang Y, Zhou H, Jiang Z, Wu D, Zhuang J, Li W, Jiang Q, Wang X, Huang J, Zhu H, Yang L, Du X, Li F, Xia R, Zhang F, Hu J, Li Y, Hu Y, Liu J, Jin C, Sun K, Zhou Z, Wu L, Yin H, Suo S, Yu W, Jin J.
Zhang Y, et al.
Am J Hematol. 2024 Apr;99(4):774-779. doi: 10.1002/ajh.27245. Epub 2024 Feb 11.
Am J Hematol. 2024.
PMID: 38343062
Clinical Trial.
Item in Clipboard
Phosphoproteomic Characterization and Kinase Signature Predict Response to Venetoclax Plus 3+7 Chemotherapy in Acute Myeloid Leukemia.
Jin J, Hou S, Yao Y, Liu M, Mao L, Yang M, Tong H, Zeng T, Huang J, Zhu Y, Wang H.
Jin J, et al.
Adv Sci (Weinh). 2024 Mar;11(11):e2305885. doi: 10.1002/advs.202305885. Epub 2023 Dec 31.
Adv Sci (Weinh). 2024.
PMID: 38161214
Free PMC article.
Item in Clipboard
Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML.
Ling Q, Zhou Y, Qian Y, Qian J, Zhang Y, Wang J, Zhu Y, Zhou Y, Wei J, Yang C, Sun J, Yu W, Jin J, Zhang X.
Ling Q, et al.
Biomark Res. 2023 Dec 5;11(1):105. doi: 10.1186/s40364-023-00547-9.
Biomark Res. 2023.
PMID: 38053201
Free PMC article.
Item in Clipboard
The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019.
Yao Y, Lin X, Li F, Jin J, Wang H.
Yao Y, et al.
Biomed Eng Online. 2022 Jan 11;21(1):4. doi: 10.1186/s12938-021-00973-6.
Biomed Eng Online. 2022.
PMID: 35016695
Free PMC article.
Item in Clipboard
Cite
Cite